Schizophrenic Patients Taking Part in Integrated Care Program

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Total Enrollment

20 participants

Study Classification

OBSERVATIONAL

Study Start Date

2008-01-31

Study Completion Date

2008-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Purpose of this non-interventional study (NIS) is to assess the effect of the participation in an integrated care program on treatment outcomes in patients treated with Seroquel for schizophrenia.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Schizophrenia Schizoaffective Disorder Schizophreni-form Disorder Delusional Disorder Psychotic Disorder Not Otherwise Specified

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Schizophrenia Integrated care program Seroquel

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

All

Schizophrenic outpatients who are treated with Seroquel IR and who are additionally intended to start with an integrated care program

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Outpatients suffering from schizophrenia, schizoaffective disorder, schizophreni-form disorder, delusional disorder or psychotic disorder not otherwise specified
* Age 18 - 65 years
* Current stable treatment with Seroquel according to SmPC since at least 2 months
* Given consent to take part in an integrated care program prior to study startWritten informed consent to take part in this NIS

Exclusion Criteria

* Presence of any contraindication as described in the SmPC
* Cancellation of participation in the integrated care program

Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Sandra Liedtke, MD

Role: STUDY_DIRECTOR

AstraZeneca

Martin Lambert, PD, MD

Role: PRINCIPAL_INVESTIGATOR

University of Hamberg

Review additional registry numbers or institutional identifiers associated with this trial.

NIS-NDE-SER-2007/1

Identifier Type: -

Identifier Source: org_study_id

Schizophrenic Patients Taking Part in Integrated Care Program

Study Results

Basic Information

Brief Summary

Detailed Description

Conditions

Keywords

Study Design

Study Groups

All

Eligibility Criteria

Inclusion Criteria

Exclusion Criteria

Sponsors

acromion GmbH

AstraZeneca

Principal Investigators

Sandra Liedtke, MD

Martin Lambert, PD, MD

Locations

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Countries

Other Identifiers

NIS-NDE-SER-2007/1